Virginia Retirement Systems ET AL bought a new position in Sarepta Therapeutics Inc (NASDAQ:SRPT) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,100 shares of the biotechnology company’s stock, valued at approximately $503,000.

Other hedge funds have also recently modified their holdings of the company. Ameritas Investment Partners Inc. increased its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Sarepta Therapeutics in the 3rd quarter worth about $204,000. Bayesian Capital Management LP acquired a new position in Sarepta Therapeutics in the 2nd quarter worth about $206,000. Finally, Strs Ohio acquired a new position in Sarepta Therapeutics in the 3rd quarter worth about $208,000. 82.02% of the stock is currently owned by institutional investors.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Douglas S. Ingram bought 38,138 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the purchase, the chief executive officer now owns 420,196 shares in the company, valued at $22,035,078.24. The disclosure for this purchase can be found here. In the last three months, insiders have sold 28,167 shares of company stock worth $1,497,619. 9.60% of the stock is currently owned by insiders.

SRPT has been the topic of several research reports. Goldman Sachs Group reaffirmed a “buy” rating and issued a $71.00 target price on shares of Sarepta Therapeutics in a research report on Friday, October 6th. ValuEngine lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Oppenheimer reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. SunTrust Banks reaffirmed a “buy” rating and issued a $56.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the company’s stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $64.14.

Sarepta Therapeutics Inc (NASDAQ SRPT) opened at $54.26 on Monday. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics Inc has a fifty-two week low of $26.26 and a fifty-two week high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the prior year, the firm posted ($0.95) EPS. equities analysts anticipate that Sarepta Therapeutics Inc will post -3.11 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/11/virginia-retirement-systems-et-al-buys-shares-of-11100-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.